Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          HHS Search block
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              About
                              News
                              HHS and the Cohen Foundation Announce Phase 1 Winners in LymeX Diagnostics Prize
 Navigate to:
  News
    
                                    
                                            
            
      
      
      
      Blog
    
                                    
                                            
            
      
      
      
      HHS Live
    
                                    
                                            
            
      
      
      
      Podcasts
    
                                    
                                            
            
      
      
      
      Media Guidelines for HHS EmployeesText resize icon

                    




**FOR IMMEDIATE RELEASE November 9, 2022**

        **Contact: 
                                    ASH Media**
          202-205-0143ashmedia@hhs.gov

          HHS and the Cohen Foundation Announce Phase 1 Winners in LymeX Diagnostics Prize
    
    

      *Transformative innovations are advancing the next generation of Lyme disease diagnostics*

Today, the U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation (Cohen Foundation) announced 10 Phase 1 winners in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) competition to accelerate the development of Lyme disease diagnostics. Phase 1 called on scientific, technical, and clinical experts to submit innovative methods for detecting active Lyme disease infections in people. The ultimate goal of the multiphase competition is to nurture the development of diagnostics toward Food and Drug Administration review.

“The winning solutions demonstrate great potential to make transformative innovation a reality for so many Americans,” said Assistant Secretary for Health Admiral Rachel L. Levine, M.D. “Through the LymeX Diagnostics Prize we are using open innovation to accelerate diagnostic breakthroughs, drive cross-sector collaboration, and put patients at the center of scientific discovery.”

From May to August 2022, Phase 1 received 52 solutions for detecting active Lyme disease infections in people. Solutions incorporated techniques such as radiological imaging, genomics sequencing, and microfluidics. Submissions also leveraged and translated approaches used in diagnosing other infectious diseases, including COVID-19. Technical reviewers initially evaluated this highly competitive field, and then the competition judging panel assessed submissions according to official evaluation criteria.

“Early detection and treatment are essential in the fight against this debilitating disease. The Phase 1 winning solutions provide hope for a future in which anyone can quickly and easily get an accurate Lyme disease diagnosis,” said Cohen Foundation President Alexandra Cohen. “We look forward to advancing the next generation of innovative Lyme disease diagnostics and providing the necessary structure for winners on their path to FDA review and approval.”

HHS congratulates the Phase 1 winners, who will each receive $100,000 and an invitation to participate in a second phase, subject to the availability of future funding:

**BlueArc Biosciences Inc.** *Ultra-Sensitive Direct Diagnostic for Early Lyme Disease.*A molecular diagnostic blood test for *Lyme B. burgdorferi s.l*. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.
	**Drexel University College of Medicine.** *Glycoproteomic Approach to Lyme Disease Diagnostics.* A small-volume serum test using glycan biomarkers to detect active Lyme disease infection, track treatment response, and distinguish between diseases with similar symptoms.
	**George Mason University**. *Borrelia Derived, Sequence-Specific Novel Diagnostic Peptides.* A urine direct test that targets absolutely specific protein molecules and would provide direct information about pathogen activity.
	**HelixBind Inc.** *Ultra-Sensitive Direct Detection of Active Borrelia Infections.* A test combining novel sample preparation and artificial nucleic acid detection to identify active infection in whole blood, synovial fluid, and cerebrospinal fluid.
	**InBios International Inc.** *Early Lyme Diagnosis Using a Microarray Immunoassay with Machine Learning.* An automated, quantified, array-based serum test using machine learning to improve sensitivity in categorizing specimens.
	**Massachusetts General Hospital.** *Cell-free Target Capture Sequencing for the Diagnosis of Lyme Disease.* A plasma test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.
	**Serimmune Inc.** *NGS-based Precision Serology for the Diagnosis of Tick-borne Disease.*A universal multiplex serum test that incorporates patient-centric surveillance testing, population data, and machine learning to enhance understanding of tick-borne diseases.
	**T2 Biosystems Inc.** *T2Lyme Panel Direct Detection of Active Lyme Disease.*A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.
	**Tufts University.** *Antiphospholipid Antibodies for Tracking Lyme Disease After Treatment.*A serum test targeting a unique antibody that would more accurately identify early infection and allow clinicians to optimize additional treatment.
	**Virginia Tech.** *Detecting Release of Peptidoglycan for Direct Lyme Disease Diagnosis.* A test using monoclonal antibodies in conjunction with immuno-PCR to detect a unique *B. burgdorferi* biomarker in multiple biofluids.The Lyme-disease-causing bacterium is complex, and collaboration is vital to accelerating innovation in disease diagnostics. The current two-tier serological testing system to detect Lyme disease relies on the presence of antibodies and can only be used accurately four to six weeks after infection. The LymeX Diagnostics Prize’s open innovation model is accelerating discovery and development by offering funding alongside exclusive access to key resources and collaboration opportunities—helping innovators take their solutions from concept to the healthcare market. From planning workshops to the multidisciplinary group of technical reviewers and judges, the LymeX Diagnostics Prize has brought together patients, advocates, academia, nonprofits, industry, and government to address this urgent patient need.

At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2. Future phases are expected to focus on clinical and nonclinical validation of diagnostic tests that detect active infection by Lyme-disease-causing bacteria, as well as readiness for regulatory submission and market entry. Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Cohen Foundation, $9 million in additional LymeX prizes are projected to be available in proposed future phases.

To learn more and receive future updates, visit LymeXDiagnosticsPrize.com and subscribe to the competition newsletter.

**About LymeX**

The LymeX Diagnostics Prize is sponsored by the LymeX Innovation Accelerator, a partnership between the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation. LymeX is the world’s largest public-private partnership for Lyme disease, fostering collaborative innovation among patients and advocates, academia, nonprofits, industry, and government. As a component of a larger moonshot, LymeX is identifying, developing, and implementing advancements in Lyme disease care. In addition to accelerating next-generation diagnostics, LymeX is spearheading development of human-centered solutions and fostering breakthroughs in education and awareness. For more information, visit lyme-x.org.

**About the U.S. Department of Health and Human Services**

HHS enhances and protects the health and well-being of all Americans. HHS fulfills that mission by providing for effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services. For more information, visit hhs.gov.

**About the Steven & Alexandra Cohen Foundation**

The Steven & Alexandra Cohen Foundation is committed to inspiring philanthropy and community service by creating awareness, offering guidance, and leading by example to show the world what giving can do. The Foundation’s grants support nonprofit organizations based in the United States that either help people in need or solve complex problems. The Foundation is the largest private funder of Lyme and tick-borne disease research in the United States with over $75 million disbursed for groundbreaking studies in prevention, diagnostics, and treatment as well as building essential research infrastructure to catalyze innovation. The Foundation also spearheads grassroots campaigns to encourage others to give. For more information, visit steveandalex.org
  

    ###
    Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.Last revised: November 9, 2022

  
  
  







  Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up







  Subscribe to RSS
    

      Receive latest updates







  Related News Releases
    

      HHS Assistant Secretary for Health ADM Rachel Levine Statement Marking the 2-year Anniversary of the Inflation Reduction Act and its Benefits to the Climate and Health Sector
  

HHS Marks Farmworker Appreciation Day; Expands Language Access and Increases Support for Workplace Evaluations, Clinician Education, and More
  

Biden-Harris Administration Announces More Than $68 Million to Improve Access to HIV Care for Women, Infants, Children and Youth







  Related Blog Posts
    

      Change Story: Director Reginald Mebane
  

Honoring Lyme Disease Awareness Month with a Multi-Year Plan to Change the Lyme Disease Status Quo
  

The U.S. Department of Health and Human Services Is Taking Action to Strengthen Primary Care

                    
  


Media Inquiries

For general media inquiries, please contact media@hhs.gov.







  Content created by Assistant Secretary for Health (ASH) Content last reviewed November 9, 2022 Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​ Disclaimer Policy: Links with this icon () mean that you are leaving the HHS website. The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
                  Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
                  You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
                  HHS is not responsible for Section 508 compliance (accessibility) on private websites. For more information on HHS's web notification policies, see Website Disclaimers.
 Continue
                  Go back